Shifting prescribing through service insight

Cheemia supported the launch of a new product in a mature therapy area by reframing its value around clinical practice and service needs. This approach helped drive adoption in a market dominated by established prescribing habits.

The challenge

The product entered a therapy area where prescribing patterns were well established.

Although the treatment offered a clear cost advantage, uptake remained low. Medicines management teams were not yet engaged and clinicians continued prescribing familiar alternatives.

Economic arguments alone were not enough to change behaviour.

Cheemia’s approach

Cheemia repositioned the product from a cost-based proposition to a clinical and service enabler, aligning engagement with clinical practice and service delivery.

The work focused on identifying where the product could support day-to-day care, extending engagement beyond prescribers to include stakeholders involved in service delivery, such as nurses.

Key elements included:

This reframed the discussion from cost to clinical value.

Outcomes

The product became recognised as appropriate for 25–40% of clinic populations, significantly exceeding early projections.

The UK went on to become the lead growth market in Europe for the formulation, and the approach was later used as a template in other regions.